Nutex Health (NUTX) Aktievy
Nutex Health Inc. är verksamt som ett företag inom hälso- och sjukvårdstjänster i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
NUTX Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
MS
Community Contributor
Nutex (NUTX) is undervalued
I believe earnings are forecast to increase. There is robust demand and robust earnings growth.
View narrativeUS$165.64
FV
4.1% övervärderad intrinsisk rabatt19.30%
Revenue growth p.a.
38
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Nutex Health Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$172.45 |
| 52 veckors högsta | US$204.00 |
| 52 veckors lägsta | US$77.21 |
| Beta | 1.99 |
| 1 månads förändring | -3.74% |
| 3 månaders förändring | 34.90% |
| 1 års förändring | 63.94% |
| 3 års förändring | 248.38% |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | -97.13% |
Senaste nyheter och uppdateringar
Seeking Alpha • 13h
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)
Summary Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods. With a 6.6x GAAP TTM PE, upside catalysts include the No Surprises Enforcement Act and $356 million in accounts receivable potentially converting to cash. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 10
NUTX: Arbitration Model And Margin Gains Will Support Future Upside
Nutex Health's analyst price target has shifted from $235.50 to $266.40. Analysts point to fresh coverage highlighting its micro hospital model, arbitration driven reimbursement approach, and capital light expansion plans as key factors in their updated views.Recent updates
Seeking Alpha • 13h
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)
Summary Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods. With a 6.6x GAAP TTM PE, upside catalysts include the No Surprises Enforcement Act and $356 million in accounts receivable potentially converting to cash. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 10
NUTX: Arbitration Model And Margin Gains Will Support Future Upside
Nutex Health's analyst price target has shifted from $235.50 to $266.40. Analysts point to fresh coverage highlighting its micro hospital model, arbitration driven reimbursement approach, and capital light expansion plans as key factors in their updated views.Uppdatering av berättelse • Jun 22
NUTX: Low EV EBITDA Multiple And Buyback Activity Will Support Future Upside
Analysts nudged their Nutex Health price target to $235, pointing to what they view as a low ~3x EV/EBITDA multiple, limited existing coverage, and ongoing investor confusion around the No Surprises Act as key factors behind their valuation work. What’s in the News for Nutex Health Nutex Health reported completing a share repurchase tranche between March 5, 2026 and March 31, 2026, buying 21,086 shares, or 0.3% of outstanding shares, for a total of US$3.02 million under the buyback announced on March 5, 2026.Uppdatering av berättelse • Jun 04
NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential
Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
Uppdatering av berättelse • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Uppdatering av berättelse • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Uppdatering av berättelse • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).Uppdatering av berättelse • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Uppdatering av berättelse • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Uppdatering av berättelse • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Uppdatering av berättelse • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Uppdatering av berättelse • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Uppdatering av berättelse • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Uppdatering av berättelse • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Ny berättelse • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Analysartikel • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analysartikel • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Analysartikel • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.Aktieägarnas avkastning
| NUTX | US Healthcare | US Marknad | |
|---|---|---|---|
| 7D | 9.7% | -0.4% | 1.0% |
| 1Y | 63.9% | 33.7% | 18.4% |
Avkastning vs industri: NUTX översteg US Healthcare branschen som gav 35.8 % under det senaste året.
Avkastning vs Marknaden: NUTX översteg US marknaden som gav 19 % under det senaste året.
Prisvolatilitet
| NUTX volatility | |
|---|---|
| NUTX Average Weekly Movement | 11.6% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: NUTX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: NUTX s veckovolatilitet ( 12% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2011 | 1,037 | Tom Vo | www.nutexhealth.com |
Nutex Health Inc. är verksamt som ett företag inom hälso- och sjukvårdstjänster i USA. Verksamheten bedrivs genom tre segment: Hospital, Population Health Management (PHM) och Real Estate. Segmentet Hospital utvecklar och driver ett nätverk av mikrosjukhus, specialistsjukhus och öppenvårdsavdelningar som erbjuder hälsovårdstjänster, inklusive akutvård, slutenvård och beteendemedicinsk vård.
Nutex Health Inc. Sammanfattning av grunderna
| NUTX grundläggande statistik | |
|---|---|
| Börsvärde | US$1.14b |
| Vinst(TTM) | US$179.92m |
| Intäkter(TTM) | US$846.72m |
6.6x
P/E-förhållande1.4x
P/S-förhållandeÄr NUTX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| NUTX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$846.72m |
| Kostnad för intäkter | US$385.19m |
| Bruttovinst | US$461.53m |
| Övriga kostnader | US$281.61m |
| Intäkter | US$179.92m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 26.27 |
| Bruttomarginal | 54.51% |
| Nettovinstmarginal | 21.25% |
| Skuld/egenkapitalförhållande | 7.8% |
Hur har NUTX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/12 03:48 |
| Aktiekurs vid dagens slut | 2026/08/12 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Nutex Health Inc. bevakas av 6 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| William Sutherland | Benchmark Company |
| Anderson Schock | B. Riley Securities, Inc. |
| Eugene Mannheimer | Freedom Capital Markets |